These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16020669)

  • 1. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
    Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
    Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
    Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
    Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
    Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
    Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.
    Watanabe M; Dewan MZ; Taira M; Shoda M; Honda M; Sata T; Higashihara M; Kadin ME; Watanabe T; Yamamoto N; Umezawa K; Horie R
    Lab Invest; 2007 Apr; 87(4):372-82. PubMed ID: 17310217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
    Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
    Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
    Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
    Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
    Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
    Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
    Ramos PMM; Pezuk JA; Castro-Gamero AM; Oliveira HF; Scrideli CA; Umezawa K; Tone LG
    Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo.
    Ito K; Nakazato T; Xian MJ; Yamada T; Hozumi N; Murakami A; Ohigashi H; Ikeda Y; Kizaki M
    Cancer Res; 2005 May; 65(10):4417-24. PubMed ID: 15899834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
    Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
    Meng Z; Mitsutake N; Nakashima M; Starenki D; Matsuse M; Takakura S; Namba H; Saenko V; Umezawa K; Ohtsuru A; Yamashita S
    Endocrinology; 2008 Nov; 149(11):5357-65. PubMed ID: 18653704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.
    Miyake A; Dewan MZ; Ishida T; Watanabe M; Honda M; Sata T; Yamamoto N; Umezawa K; Watanabe T; Horie R
    Microbes Infect; 2008 Jun; 10(7):748-56. PubMed ID: 18538617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
    Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
    Yasuda A; Kondo S; Nagumo T; Tsukamoto H; Mukudai Y; Umezawa K; Shintani S
    Oral Oncol; 2011 May; 47(5):334-9. PubMed ID: 21459660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Berenson JR; Ma HM; Vescio R
    Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.